Negative results of humoral immunity after anti-SARS-CoV-2 vaccination in patient with advanced ovarian cancer treated with maintenance immunotherapy and targeted therapy: a clinical case and а literature review
https://doi.org/10.18027/2224-5057-2021-11-1-5-8
Abstract
Gam-COVID-Vac (Sputnik V, Gamaleya Research Institute of Epidemiology and Microbiology of Ministry of Health of Russian Federation) is an adenovirus viral vector vaccine for COVID-19 which became the very first vaccine against SARS-CoV-2 registered in Russia and worldwide. The vaccine efficacy and safety in cancer patients is unknown. We present a clinical case of the absence of post-vaccination immunity after the use of Gam-COVID-Vac in a patient with advanced ovarian cancer treated with maintenance targeted and immunotherapy and discuss it in the light of the available evidence base on the effectiveness of other anti-SARS CoV-2 vaccines in cancer patients.
About the Author
A. A. Rumyantsev
N. N. Blokhin National Medical Research Center of Oncology
Russian Federation
Russian Federation
Aleksey A. Rumyantsev, MD, PhD, Oncologist, Oncology Department of Medicinal Methods of Treatment (Chemotherapy) No. 4
Moscow
References
1. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatulin AI, Shcheblyakov DV, Dzharullaeva AS, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1 / 2 studies from Russia. The Lancet. 2020;396 (10 255):887–897. doi:10.1016/S0140–6736(20)31866–3
2. Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur J Cancer. 2020;139:43–50. doi:10.1016j.ejca.2020.08.011
3. Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, et al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet. 2021;397 (10 275):671–681. doi:10.1016/S0140–6736(21)00234–8
4. Bucci EM, Berkhof J, Gillibert A, Gopalakrishna G, Calogero RA, Bouter LM, et al. Data discrepancies and substandard reporting of interim data of Sputnik V phase 3 trial. The Lancet. 2021;397 (10 288):1881–1883. doi:10.1016/S0140–6736(21)00899–0
5. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, del Molino del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22 (6):765–778. doi:10.1016/S1470–2045(21)00213–8
6. Gauci M–L, Coutzac C, Houot R, Marabelle A, Lebbé C. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC). Eur J Cancer. 2021;148:121–123. doi:10.1016/j.ejca.2021.02.003
7. Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, et al. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncol. Published online May 28, 2021. doi:10.1001/jamaoncol.2021.2155
Review
For citations:
Rumyantsev A.A. Negative results of humoral immunity after anti-SARS-CoV-2 vaccination in patient with advanced ovarian cancer treated with maintenance immunotherapy and targeted therapy: a clinical case and а literature review. Malignant tumours. 2021;11(1):5-8. (In Russ.) https://doi.org/10.18027/2224-5057-2021-11-1-5-8
Views:
1056
Email this article 